Newsbenzinga
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication
· Published
Article summary
Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved clinical trial limitations.
An excerpt from the original article.
Comments —
Loading comments…